



Pressure BioSciences, Inc.

Ticker: PBIO (OTCQB)

Corporate Profile

as of November 19, 2016

Pressure BioSciences, Inc. (OTCQB: PBIO) is a medical research products and technology company. PBI, based in South Easton, Massachusetts, serves academic and government laboratories, as well as biotechnology, pharmaceutical, and other life sciences companies.

PBI announced the sale of new instrumentation of which three of the five machines were chosen to go to the cancer research project Cancer Moonshot, a project led by Vice President Joe Biden which aims to make more therapies available to more patients, while also improving the ability to prevent cancer and enhance early detection.

PBI recently signed an exclusive, two-year co-marketing agreement with a large strategic partner named SCIEX, which offers tremendous potential for revenue growth. SCIEX is a global leader in life sciences analytical technologies and a wholly-owned subsidiary of the Danaher Corporation (NYSE: DHR).

The PBI technology platform is based on constant (i.e., static) and alternating (i.e., Pressure Cycling Technology, or PCT) hydrostatic pressure; if used properly, pressure can help control the actions of molecules in biological samples, which can then have significant positive effects on scientific research studies.

PBI's market consists of an estimated 500,000 scientists in over 80,000 research laboratories worldwide. PBI focuses on biomarker/drug discovery and design, as well as forensics. Today the Company has approximately 150 worldwide customers that could be expanded to areas such as: bio-therapeutics characterization, soil & plant biology, vaccine development, counter- bioterror applications and DNA studies.

The Company continues to meet or exceed its publicly-disclosed goals, and continues to give guidance that it anticipates an up-listing to a major exchange within the next year. We believe PBIO can soon surpass its 52-week high in share price as it continues to gain momentum.

Table with 4 main sections: Income Statement, Balance Sheet, Cash Flow Statement, and Equity. Columns include FY 2014, FY 2015, and 9/30/16.



Sector: Healthcare
Industry: Medical Devices & Technology

Website: www.pressurebiosciences.com

Key Statistics

Table of key statistics including Price (11/18/2016), 52 Week High, 52 Week Low, Avg. Vol (30day), Beta, Market Cap (Interday), Price/Sales (TTM), Insider Ownership (%), Shares Outstanding (M), Float (M), and EPS(9m).

Recent 2016 Highlights

- November 15, PBI announced 22% product revenue growth for the first 9 months, including record instrument and consumable sales.
November 14, PBI announced initial close of \$610,000 in a \$2.5 Million private placement.
July 28, 2016, PBI and SCIEX together have improved complex sample processing for higher quality results, reproducibility and depth of proteomic analysis.
March 31, 2016, PBI closed an additional \$769K in PIPE financing.

Corporate Contact Information

Pressure BioSciences Inc.
Richard T. Schumacher, CEO
14 Norfolk Ave. South Easton MA, 02375
Phone: 508-230-1828
www.pressurebiosciences.com

The information presented herein is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities. This corporate profile is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources...